Elicera Therapeutics' board and management buy shares
Gothenburg, July 5, 2021 - Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company that develops immunooncological treatments focusing on CAR T-cells and oncolytic viruses, announced today that the board and management have bought shares in the company.Purchase of shares Eight people on the board and management have bought a total of 132,591 shares in Elicera outside the market. Those who bought shares include the chairman of the board, the CEO, the CSO and the CFO.